Mesoblast (MEOBF) Total Debt Growth (3y) (2021 - 2026)
Powered by 
Analysis
Mesoblast (MEOBF) Total Debt Growth (3y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | - |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | - |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | - |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | -16.70% |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | - |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | - |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | - |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | -11.80% |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | - |
| 10 | Mesoblast | 246.02 Mn | 143.11 Mn | - | 21.20% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 21.20% |
| Dec 31, 2025 | 124.00% |
| Jun 30, 2025 | 121.00% |
| Dec 31, 2024 | 49.84% |
| Jun 30, 2024 | -36.13% |
| Dec 31, 2023 | -41.01% |
| Jun 30, 2023 | -43.19% |
| Mar 31, 2023 | -35.30% |
| Dec 31, 2022 | -32.05% |
| Sep 30, 2022 | -33.72% |
| Jun 30, 2022 | -28.98% |
| Mar 31, 2022 | -16.12% |
| Dec 31, 2021 | 18.90% |
| Sep 30, 2021 | -4.16% |
| Jun 30, 2021 | -3.61% |
| Mar 31, 2021 | 18.79% |